Patents by Inventor Thomas Kruse

Thomas Kruse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Glucagon Analogues
    Publication number: 20160002311
    Abstract: The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
    Type: Application
    Filed: August 17, 2015
    Publication date: January 7, 2016
    Inventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen, Jacob Kofoed, Kirsten Dahl
  • STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE
    Publication number: 20150374794
    Abstract: The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.
    Type: Application
    Filed: August 26, 2015
    Publication date: December 31, 2015
    Inventors: Ulrich Sensfuss, Thomas Kruse, Jesper F. Lau
  • Novel Glucagon Analogues
    Publication number: 20150368313
    Abstract: The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
    Type: Application
    Filed: July 31, 2015
    Publication date: December 24, 2015
    Inventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Thomas N. Krogh, Ulrich Sensfuss
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20150274801
    Abstract: The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
    Type: Application
    Filed: June 15, 2015
    Publication date: October 1, 2015
    Inventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen
  • Double-Acylated GLP-1 Derivatives with a Linker
    Publication number: 20150210745
    Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from HOOC—(CH2)x-CO—*, and Chem. 1: HOOC—C6H4-0-(CH2)y-CO—*, Chem. 2: in which x is an integer in the range of 6-18, and y is an integer in the range of 3-17; and the linker comprises *—NH—(CH2)q-CH[(CH2)w-NH2]-CO—*, Chem. 3: wherein q is an integer in the range of 0-5, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof.
    Type: Application
    Filed: January 29, 2015
    Publication date: July 30, 2015
    Inventors: Jacob Kofoed, Jesper Lau, Lars Linderoth, Patrick William Garibay, Thomas Kruse
  • NOVEL GLUCAGON ANALOGUES
    Publication number: 20150182594
    Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
    Type: Application
    Filed: February 24, 2015
    Publication date: July 2, 2015
    Inventors: Jesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
  • Peptides derivatized with A-B-C-D- and their therapeutical use
    Patent number: 9067977
    Abstract: The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogs thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: June 30, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Soeren Oestergaard, Steffen Reedtz-Runge, Henning Thoegersen
  • Polypeptide protracting tags
    Patent number: 9061067
    Abstract: The invention relates to methods for increasing the plasma half-life of a molecule, such as human growth hormone, comprising covalently linking the molecule to a heterocyclic carboxylic acid bioisostere.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: June 23, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dörwald, Christine Bruun Schiødt, Thomas Kruse Hansen, Kjeld Madsen
  • Amylin analogues and pharmaceutical compositions thereof
    Patent number: 9029325
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 12, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
  • Amylin analogs and pharmaceutical compositions thereof
    Patent number: 9023789
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analog of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: May 5, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
  • Microcoating comprising siloxanes
    Patent number: 9011586
    Abstract: The invention relates to a binding agent comprising an aqueous, film-forming, polymeric siloxane. The invention also relates to a coating agent that is produced using said binding agent and to a workpiece that is coated with said coating agent.
    Type: Grant
    Filed: March 21, 2005
    Date of Patent: April 21, 2015
    Assignee: Ewald Dörken AG
    Inventors: Thomas Kruse, Bettina Werner, Gerhard Reusmann
  • Double-acylated GLP-1 derivatives with a linker
    Patent number: 9006178
    Abstract: The invention relates to a derivative of a GLP-1 analog, which analog comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC—(CH2)x—CO—*, and Chem. 2: HOOC—C6H4-0-(CH2)y—CO—*, in which x is an integer in the range of 6-18, and y is an integer in the range of 3-17; and the linker comprises Chem. 3: *—NH—(CH2)q—CH[(CH2)w—NH2]—CO—*, wherein q is an integer in the range of 0-5, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: April 14, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Jacob Kofoed, Jesper Lau, Lars Linderoth, Patrick William Garibay, Thomas Kruse
  • Antimicrobial Peptide Variants and Polynucleotides Encoding Same
    Publication number: 20150031601
    Abstract: The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: August 11, 2014
    Publication date: January 29, 2015
    Applicant: ADDENIUM BIOTECH APS
    Inventors: Hans-Henrik Kristensen Hoegenhaug, Per Holse Mygind, Thomas Kruse, Dorotea Raventos Segura, Dorthe Hoj Sandvang, Soren Neve
  • GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE
    Publication number: 20150025003
    Abstract: The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 22, 2015
    Inventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Thomas Kruse, Patrick W. Garibay, Steffen Reedtz-Runge, Henning Thoegersen, Ingrid Pettersson
  • METHOD AND A DEVICE FOR THE MANUFACTURE OF A FIBRE COMPOSITE COMPONENT, AND A FIBRE COMPOSITE COMPONENT
    Publication number: 20150004357
    Abstract: A method for the manufacture of a fibre composite component with at least one opening, which is edged by an integral collar, a device for the execution of a method of this type with a mould core, which has at least one convexity for the formation of a component section in the form of a bulge, also a fibre composite component with a multiplicity of openings, each of which is edged by an integral collar.
    Type: Application
    Filed: February 29, 2012
    Publication date: January 1, 2015
    Applicant: AIRBUS OPERATIONS GMBH
    Inventors: Marc Schimmler, Bernd Raeckers, Thomas Kruse, Wolfgang Schulze
  • Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
    Patent number: 8895694
    Abstract: The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: November 25, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Steffen Reedtz-Runge, Henning Thøgersen, Ingrid Pettersson
  • Amylin derivatives
    Patent number: 8895504
    Abstract: Amylin derivatives, pharmaceutical compositions containing such derivatives, as well as methods of treating diabetes and hyperglycaemia are disclosed.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: November 25, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Lauge Schäffer, Thomas Kruse, Jesper Lau, Henning Thøgersen
  • METHOD FOR SETTING UP A FUNCTIONALITY FOR A CONTROL UNIT
    Publication number: 20140330400
    Abstract: A method is provided for populating a function for a control unit with data, in which method measurements are performed on a system at different measuring points on a test stand, and a global data-based model is set up based on the obtained measured values, and virtual measurements which simulate real measurements on the test stand are carried out on the global data-based model, and uncertainties for virtual measured values of the virtual measurements are determined from the global data-based model, the uncertainties of the virtual measured values being taken into account when populating the function for the control unit with data.
    Type: Application
    Filed: July 19, 2012
    Publication date: November 6, 2014
    Inventors: Heiner Markert, Thomas Kruse, Volker Imhof, Thorsten Huber, Rene Diener, Ernst Kloppenburg, Felix Streichert, Holger Ulmer, Stefan Angermaier
  • Structural component with improved conductivity and mechanical strength, and a method for its manufacture
    Patent number: 8864072
    Abstract: A structural component includes a fiber composite material structure having an outer surface and an electrically conductive metal profile disposed on the outer surface of the fiber composite material structure. The metal profile provides provide improved electrical conductivity of the structural component and component protection.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: October 21, 2014
    Assignee: Airbus Operations GmbH
    Inventors: Jens Telgkamp, Wolfgang Schulze, Thomas Kruse
  • Antimicrobial peptide variants and polynucleotides encoding same
    Patent number: 8835604
    Abstract: The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: September 16, 2014
    Assignee: Adenium Biotech Aos
    Inventors: Hans-Henrik Kristensen Hoegenhaug, Per Holse Mygind, Thomas Kruse, Dorotea Raventos Segura, Dorthe Hoj Sandvang, Soren Neve